131 related articles for article (PubMed ID: 11783773)
1. Acyclovir-valaciclovir equilibrium between peritoneal fluid and plasma.
Stathoulopoulou F; Dhillon S; Stathakis C; Stamatiadis D
Perit Dial Int; 2001; 21(6):614-7. PubMed ID: 11783773
[No Abstract] [Full Text] [Related]
2. Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.
Izzedine H; Mercadal L; Aymard G; Launay-Vacher V; Martinez V; Issad B; Deray G
Am J Nephrol; 2001; 21(2):162-4. PubMed ID: 11359026
[TBL] [Abstract][Full Text] [Related]
3. Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid.
de Bony F; Bidault R; Peck R; Posner J
J Antimicrob Chemother; 1996 Feb; 37(2):383-7. PubMed ID: 8707752
[TBL] [Abstract][Full Text] [Related]
4. Rapid determination of valaciclovir and acyclovir in human biological fluids by high-performance liquid chromatography using isocratic elution.
Pham-Huy C; Stathoulopoulou F; Sandouk P; Scherrmann JM; Palombo S; Girre C
J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(1):47-53. PubMed ID: 10517221
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
Steingrimsdottir H; Gruber A; Palm C; Grimfors G; Kalin M; Eksborg S
Antimicrob Agents Chemother; 2000 Jan; 44(1):207-9. PubMed ID: 10602752
[TBL] [Abstract][Full Text] [Related]
6. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster.
Smiley ML; Murray A; de Miranda P
Adv Exp Med Biol; 1996; 394():33-9. PubMed ID: 8815698
[No Abstract] [Full Text] [Related]
7. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of acyclovir in the cat.
Owens JG; Nasisse MP; Tadepalli SM; Dorman DC
J Vet Pharmacol Ther; 1996 Dec; 19(6):488-90. PubMed ID: 8971679
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
[TBL] [Abstract][Full Text] [Related]
10. Syntheses, chemical and enzymatic stability of new poly(ethylene glycol)-acyclovir prodrugs.
Zacchigna M; Di Luca G; Maurich V; Boccù E
Farmaco; 2002 Mar; 57(3):207-14. PubMed ID: 11989799
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients.
Stathoulopoulou F; Dhillon S; Thodis H; Stathakis C; Vargemezis V
Nephron; 2002 May; 91(1):164-6. PubMed ID: 12021536
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of new antiherpes agents: famciclovir and valacyclovir.
Stein GE
J Am Pharm Assoc (Wash); 1997; NS37(2):157-63. PubMed ID: 9069689
[TBL] [Abstract][Full Text] [Related]
13. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
Beutner KR
Antiviral Res; 1995 Dec; 28(4):281-90. PubMed ID: 8669888
[TBL] [Abstract][Full Text] [Related]
14. Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin.
Soul-Lawton JH; Weatherley BC; Posner J; Layton G; Peck RW
Br J Clin Pharmacol; 1998 Jan; 45(1):87-9. PubMed ID: 9489600
[TBL] [Abstract][Full Text] [Related]
15. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS.
Dias C; Nashed Y; Atluri H; Mitra A
Curr Eye Res; 2002 Oct; 25(4):243-52. PubMed ID: 12658558
[TBL] [Abstract][Full Text] [Related]
16. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
Soul-Lawton J; Seaber E; On N; Wootton R; Rolan P; Posner J
Antimicrob Agents Chemother; 1995 Dec; 39(12):2759-64. PubMed ID: 8593015
[TBL] [Abstract][Full Text] [Related]
17. [Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement?].
Peyrière H; Branger B; Bengler C; Vécina F; Pinzani V; Hillaire-Buys D; Blayac JP
Rev Med Interne; 2001 Mar; 22(3):297-303. PubMed ID: 11270274
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
Jacobson MA; Gallant J; Wang LH; Coakley D; Weller S; Gary D; Squires L; Smiley ML; Blum MR; Feinberg J
Antimicrob Agents Chemother; 1994 Jul; 38(7):1534-40. PubMed ID: 7979285
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
[TBL] [Abstract][Full Text] [Related]
20. [Prodrugs].
Järvinen T; Rautio J; Niemi R
Duodecim; 1997; 113(24):2564-8. PubMed ID: 10892164
[No Abstract] [Full Text] [Related]
[Next] [New Search]
